Cargando…
β‐arrestin1‐medieated inhibition of FOXO3a contributes to prostate cancer cell growth in vitro and in vivo
Recently, β‐arrestin1 has been indicated as a prostate cancer promoter through promoting cell proliferation and epithelial to mesenchymal transition, but its underlying mechanism remains unclear. Here, our data revealed that β‐arrestin1 could promote cell growth through inhibiting the transcriptiona...
Autores principales: | Kong, Zhenzhen, Deng, Tuo, Zhang, Mengping, Zhao, Zhijian, Liu, Yang, Luo, Lianmin, Cai, Chao, Wu, Wenqi, Duan, Xiaolu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989847/ https://www.ncbi.nlm.nih.gov/pubmed/29676828 http://dx.doi.org/10.1111/cas.13619 |
Ejemplares similares
-
Partial versus radical nephrectomy for T1b-2N0M0 renal tumors: A propensity score matching study based on the SEER database
por: Zhang, Mengping, et al.
Publicado: (2018) -
β-Arrestin2 promotes docetaxel resistance of castration-resistant prostate cancer via promoting hnRNP A1-mediated PKM2 alternative splicing
por: Zhou, Yuhao, et al.
Publicado: (2023) -
Autophagy inhibition attenuates hyperoxaluria-induced renal tubular oxidative injury and calcium oxalate crystal depositions in the rat kidney
por: Duan, Xiaolu, et al.
Publicado: (2018) -
Impact of dyslipidemia on 24-h urine composition in adults without urolithiasis
por: Cai, Chao, et al.
Publicado: (2018) -
Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis
por: Deng, Tuo, et al.
Publicado: (2020)